126 related articles for article (PubMed ID: 36914062)
1. Epigenome editing based on CRISPR/dCas9
Huang H; Zhang W; Zhang J; Zhao A; Jiang H
Exp Cell Res; 2023 Apr; 425(2):113551. PubMed ID: 36914062
[TBL] [Abstract][Full Text] [Related]
2. CRISPR/dCas9-mediated activation of multiple endogenous target genes directly converts human foreskin fibroblasts into Leydig-like cells.
Huang H; Zou X; Zhong L; Hou Y; Zhou J; Zhang Z; Xing X; Sun J
J Cell Mol Med; 2019 Sep; 23(9):6072-6084. PubMed ID: 31264792
[TBL] [Abstract][Full Text] [Related]
3. Leydig-like cells derived from reprogrammed human foreskin fibroblasts by CRISPR/dCas9 increase the level of serum testosterone in castrated male rats.
Huang H; Zhong L; Zhou J; Hou Y; Zhang Z; Xing X; Sun J
J Cell Mol Med; 2020 Apr; 24(7):3971-3981. PubMed ID: 32160419
[TBL] [Abstract][Full Text] [Related]
4. Stabilization of Foxp3 expression by CRISPR-dCas9-based epigenome editing in mouse primary T cells.
Okada M; Kanamori M; Someya K; Nakatsukasa H; Yoshimura A
Epigenetics Chromatin; 2017; 10():24. PubMed ID: 28503202
[TBL] [Abstract][Full Text] [Related]
5. Targeted Modification of Epigenetic Marks Using CRISPR/dCas9-SunTag-Based Modular Epigenetic Toolkit.
Song MK; Kim YS
Methods Mol Biol; 2024; 2761():81-91. PubMed ID: 38427231
[TBL] [Abstract][Full Text] [Related]
6. CRISPR/dCas9-mediated epigenetic modification reveals differential regulation of histone acetylation on Aspergillus niger secondary metabolite.
Li X; Huang L; Pan L; Wang B; Pan L
Microbiol Res; 2021 Apr; 245():126694. PubMed ID: 33482403
[TBL] [Abstract][Full Text] [Related]
7. Epigenome editing of the CFTR-locus for treatment of cystic fibrosis.
Kabadi AM; Machlin L; Dalal N; Lee RE; McDowell I; Shah NN; Drowley L; Randell SH; Reddy TE
J Cyst Fibros; 2022 Jan; 21(1):164-171. PubMed ID: 34049825
[TBL] [Abstract][Full Text] [Related]
8. Direct Reprogramming of Mouse Fibroblasts toward Leydig-like Cells by Defined Factors.
Yang Y; Li Z; Wu X; Chen H; Xu W; Xiang Q; Zhang Q; Chen J; Ge RS; Su Z; Huang Y
Stem Cell Reports; 2017 Jan; 8(1):39-53. PubMed ID: 28017657
[TBL] [Abstract][Full Text] [Related]
9. Highly specific epigenome editing by CRISPR-Cas9 repressors for silencing of distal regulatory elements.
Thakore PI; D'Ippolito AM; Song L; Safi A; Shivakumar NK; Kabadi AM; Reddy TE; Crawford GE; Gersbach CA
Nat Methods; 2015 Dec; 12(12):1143-9. PubMed ID: 26501517
[TBL] [Abstract][Full Text] [Related]
10. Temporal and Spatial Epigenome Editing Allows Precise Gene Regulation in Mammalian Cells.
Kuscu C; Mammadov R; Czikora A; Unlu H; Tufan T; Fischer NL; Arslan S; Bekiranov S; Kanemaki M; Adli M
J Mol Biol; 2019 Jan; 431(1):111-121. PubMed ID: 30098338
[TBL] [Abstract][Full Text] [Related]
11. Robust Transcriptional Activation in Plants Using Multiplexed CRISPR-Act2.0 and mTALE-Act Systems.
Lowder LG; Zhou J; Zhang Y; Malzahn A; Zhong Z; Hsieh TF; Voytas DF; Zhang Y; Qi Y
Mol Plant; 2018 Feb; 11(2):245-256. PubMed ID: 29197638
[TBL] [Abstract][Full Text] [Related]
12. Hepatic stellate cell reprogramming via exosome-mediated CRISPR/dCas9-VP64 delivery.
Luo N; Li J; Chen Y; Xu Y; Wei Y; Lu J; Dong R
Drug Deliv; 2021 Dec; 28(1):10-18. PubMed ID: 33336604
[TBL] [Abstract][Full Text] [Related]
13. Waking up dormant tumor suppressor genes with zinc fingers, TALEs and the CRISPR/dCas9 system.
Garcia-Bloj B; Moses C; Sgro A; Plani-Lam J; Arooj M; Duffy C; Thiruvengadam S; Sorolla A; Rashwan R; Mancera RL; Leisewitz A; Swift-Scanlan T; Corvalan AH; Blancafort P
Oncotarget; 2016 Sep; 7(37):60535-60554. PubMed ID: 27528034
[TBL] [Abstract][Full Text] [Related]
14. Comparative analysis of dCas9-VP64 variants and multiplexed guide RNAs mediating CRISPR activation.
Omachi K; Miner JH
PLoS One; 2022; 17(6):e0270008. PubMed ID: 35763517
[TBL] [Abstract][Full Text] [Related]
15. A review on CRISPR/Cas-based epigenetic regulation in plants.
Jogam P; Sandhya D; Alok A; Peddaboina V; Allini VR; Zhang B
Int J Biol Macromol; 2022 Oct; 219():1261-1271. PubMed ID: 36057300
[TBL] [Abstract][Full Text] [Related]
16. Genome and epigenome engineering CRISPR toolkit for
Williams RM; Senanayake U; Artibani M; Taylor G; Wells D; Ahmed AA; Sauka-Spengler T
Development; 2018 Feb; 145(4):. PubMed ID: 29386245
[TBL] [Abstract][Full Text] [Related]
17. Inducible CRISPR-dCas9 Transcriptional Systems for Sensing and Genome Regulation.
Wu H; Wang F; Jiang JH
Chembiochem; 2021 Jun; 22(11):1894-1900. PubMed ID: 33433941
[TBL] [Abstract][Full Text] [Related]
18. Reversing Mechanoinductive DSP Expression by CRISPR/dCas9-mediated Epigenome Editing.
Qu J; Zhu L; Zhou Z; Chen P; Liu S; Locy ML; Thannickal VJ; Zhou Y
Am J Respir Crit Care Med; 2018 Sep; 198(5):599-609. PubMed ID: 29924937
[TBL] [Abstract][Full Text] [Related]
19. In vivo epigenome editing and transcriptional modulation using CRISPR technology.
Lau CH; Suh Y
Transgenic Res; 2018 Dec; 27(6):489-509. PubMed ID: 30284145
[TBL] [Abstract][Full Text] [Related]
20. CRISPR/dCas9 for hepatic fibrosis therapy: implications and challenges.
Luo N; Zhong W; Li J; Lu J; Dong R
Mol Biol Rep; 2022 Dec; 49(12):11403-11408. PubMed ID: 35960410
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
